Haemonetics
329 hedge funds and large institutions have $4.08B invested in Haemonetics in 2025 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 93 increasing their positions, 131 reducing their positions, and 42 closing their positions.
2,695% more call options, than puts
Call options by funds: $65.6M | Put options by funds: $2.35M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
83% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 42
63% more capital invested
Capital invested by funds: $2.5B → $4.08B (+$1.57B)
9% more funds holding
Funds holding: 301 → 329 (+28)
2.11% more ownership
Funds ownership: 106.52% → 108.63% (+2.1%)
29% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 131
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$84.3M |
| 2 |
Holocene Advisors
New York
|
+$82.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$71.7M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$69.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$54.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$61.3M |
| 2 |
Millennium Management
New York
|
-$48.3M |
| 3 |
RA
Royce & Associates
New York
|
-$42.3M |
| 4 |
RRAM
River Road Asset Management
Louisville,
Kentucky
|
-$37.1M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$32.3M |
HAE Hedge Fund Activity: Q4 2025 in Review
329 of the 8,264 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q4 2025, worth a combined $4.08B — up 63% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new HAE positions and 42 closed out — a net gain of 35 holders — while 93 added to existing stakes and 131 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $84.3M. The largest seller was UBS Group, cutting an estimated $61.3M.
- 329 institutional investors held Haemonetics (HAE) as of Q4 2025, up from 301 in Q3 2025.
- Funds reported $4.08B of Haemonetics stock for Q4 2025, up 63% quarter-over-quarter.
- 77 funds opened new Haemonetics positions in Q4 2025 and 42 closed out, a net change of +35 holders.
- The largest Haemonetics buyer in Q4 2025 was Arrowstreet Capital, an estimated $84.3M added.
- The largest Haemonetics seller in Q4 2025 was UBS Group, an estimated $61.3M sold.
Based on aggregated 13F filings for Q4 2025.